La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Shanghai Universal BiotechLtd Résultats passés
Passé contrôle des critères 0/6
Shanghai Universal BiotechLtd's earnings have been declining at an average annual rate of -6.1%, while the Healthcare industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 8.4% per year. Shanghai Universal BiotechLtd's return on equity is 1.3%, and it has net margins of 2.3%.
Informations clés
-6.1%
Taux de croissance des bénéfices
-14.8%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 7.0% |
| Taux de croissance des recettes | 8.4% |
| Rendement des fonds propres | 1.3% |
| Marge nette | 2.3% |
| Prochaine mise à jour des résultats | 30 Aug 2024 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment Shanghai Universal BiotechLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 1,223 | 28 | 183 | 58 |
| 31 Dec 23 | 1,226 | 40 | 178 | 57 |
| 30 Sep 23 | 1,220 | 68 | 170 | 49 |
| 30 Jun 23 | 1,267 | 100 | 162 | 47 |
| 31 Mar 23 | 1,228 | 103 | 156 | 41 |
| 01 Jan 23 | 1,195 | 107 | 145 | 32 |
| 30 Sep 22 | 1,178 | 108 | 140 | 27 |
| 30 Jun 22 | 1,104 | 98 | 129 | 21 |
| 31 Mar 22 | 1,115 | 109 | 116 | 18 |
| 01 Jan 22 | 1,110 | 109 | 112 | 16 |
| 30 Sep 21 | 1,047 | 104 | 105 | 12 |
| 30 Jun 21 | 1,017 | 100 | 104 | 11 |
| 31 Mar 21 | 915 | 84 | 100 | 10 |
| 31 Dec 20 | 849 | 76 | 94 | 9 |
| 31 Dec 19 | 787 | 58 | 94 | 9 |
| 31 Dec 18 | 604 | 40 | 73 | 6 |
| 31 Dec 17 | 432 | 26 | 56 | 3 |
| 30 Jun 17 | 376 | 21 | 49 | 0 |
| 31 Mar 17 | 359 | 21 | 44 | 0 |
| 31 Dec 16 | 342 | 21 | 40 | 0 |
| 30 Sep 16 | 315 | 17 | 41 | 0 |
| 30 Jun 16 | 287 | 14 | 39 | 0 |
| 31 Mar 16 | 260 | 11 | 36 | 0 |
| 31 Dec 15 | 232 | 9 | 33 | 0 |
| 31 Dec 14 | 162 | 7 | 22 | 0 |
| 31 Dec 13 | 109 | 1 | 20 | 0 |
Des revenus de qualité: 301166 has a large one-off gain of CN¥22.6M impacting its last 12 months of financial results to 31st March, 2024.
Augmentation de la marge bénéficiaire: 301166's current net profit margins (2.3%) are lower than last year (8.4%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 301166's earnings have declined by 6.1% per year over the past 5 years.
Accélération de la croissance: 301166's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 301166 had negative earnings growth (-73.2%) over the past year, making it difficult to compare to the Healthcare industry average (-3.5%).
Rendement des fonds propres
ROE élevé: 301166's Return on Equity (1.3%) is considered low.